Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
| Gilead Sciences (NASDAQ: GILD) | Delayed: 150.43 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $150.43 | 52 Week High | $108.63 | |||
| Open | $150.43 | 52 Week Low | $71.39 | |||
| Day High | $150.43 | P/E | 83.11 | |||
| Day Low | $150.43 | EPS | $1.81 | |||
| Volume | 2,117 | |||||
| Sangamo Biosciences, Inc. (NASDAQ: SGMO) | Delayed: 0.18 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.18 | 52 Week High | $9.91 | |||
| Open | $0.18 | 52 Week Low | $3.10 | |||
| Day High | $0.18 | P/E | N/A | |||
| Day Low | $0.18 | EPS | $-0.48 | |||
| Volume | 450 | |||||
